Sunday, June 26, 2022

Director FOEHR MATTHEW W acquired 45,000 shares of Viking Therapeutics Inc. [VKTX]

Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Viking Therapeutics Inc. shares valued at $111,195 were purchased by FOEHR MATTHEW W on May 02. At $2.47 per share, FOEHR MATTHEW W acquired 45,000 shares. The insider’s holdings grew to 111,250 shares worth approximately $0.31 million following the completion of this transaction.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


This represents a 85.85% premium over Thursday’s closing price. Analysts at Raymond James downgraded the stock from ‘”a Strong buy”‘ to ‘”an Outperform”‘ outlook in a report released in late May. As of June 05, 2020, BMO Capital Markets has initiated its “an Outperform” rating for VKTX. Earlier on May 05, 2020, Chardan Capital Markets initiated its rating. Their recommendation was “a Buy” for VKTX stock.

Analyzing VKTX’s Price Performance

On Thursday, Viking Therapeutics Inc. [NASDAQ: VKTX] rose 9.69% to $2.83. The stock’s lowest price that day was $2.56, but it reached a high of $2.86 in the same session. During the last five days, there has been a surge of approximately 30.41%. Over the course of the year, Viking Therapeutics Inc. shares have dropped approximately -38.48%. Shares of the company reached a 52-week high of $4.93 on 01/03/22 and a 52-week low of $2.02 on 06/16/22. A 50-day SMA is recorded $2.37, while a 200-day SMA reached $4.16. Nevertheless, trading volume fell to 1.36 million shares from 0.92 million shares the previous day.

Support And Resistance Levels for Viking Therapeutics Inc. (VKTX)

According to the 24-hour chart, there is a support level at 2.64, which, if violated, would cause prices to drop to 2.45. In the upper region, resistance lies at 2.94. The next price resistance is at 3.05. RSI (Relative Strength Index) is 65.02 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.29, which suggests the price will decrease in the coming days. Percent R is at 3.57%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Is Viking Therapeutics Inc. subject to short interest?

Stocks of Viking Therapeutics Inc. saw a sharp rise in short interest on May 30, 2022 jumping by 0.83 million shares to 4.69 million. Data from Yahoo Finance shows that the short interest on Apr 28, 2022 was 3.86 million shares. A jump of 17.7% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 5.22 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.22.

Which companies own the most shares of Viking Therapeutics Inc. (VKTX)?

According to BlackRock Fund Advisors filings, the company currently owns 4,523,140 shares, which is about 5.85% of the total VKTX shares outstanding. The investor’s shares have plunged by -53,557 from its previous 13-F filing of 4576697.0 shares. With the completion of the buy transaction, The Vanguard Group, Inc.’s stake is now worth $7,893,858. Park West Asset Management LLC acquire a 52.51% interest valued at $5.48 million while Millennium Management LLC purchased a 1,296,236 stake. A total of 312,377 shares of Viking Therapeutics Inc. were bought by Dimensional Fund Advisors LP during the quarter, and -2,768,391 were sold by SSgA Funds Management, Inc. In its current portfolio, Geode Capital Management LLC holds 1,292,267 shares valued at $2.87 million.

In terms of Viking Therapeutics Inc. share price expectations, FactSet research, analysts set an average price target of $17.56 in the next 12 months, up nearly 481.4% from the previous closing price of $2.58. Analysts anticipate Viking Therapeutics Inc. stock to reach $30.00 by 2022, with the lowest price target being $10.00. On May 01, 2020, BTIG Research assigned a price target of “a Buy” to the stock and initiated coverage with a $9.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2618

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam